● Recruiting

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Condition: Primary Light-Chain Amyloidosis · Sponsor: Keymed Biosciences Co.Ltd

PhasePhase 2

Planned participants90

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis

This description comes directly from the study's public registry record.

Talk to the study team

Qian Jia · 028-88610620 · qianjia@keymedbio.com

Always discuss trial participation with your own doctor first.

Locations (2)

Peking Union Medical College Hospital	Beijing, Beijing Municipality, China	Recruiting
Institute of Hematology & Blood Diseases Hospital	Tianjin, Tianjin Municipality, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07039578